HRT Financial’s Alzamend Neuro ALZN Stock Holding History

HRT Financial’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-187	Closed	-$15K	–	2247
2023 Q4	$15K	Buy	+187	New	+$30.6K	﹤0.01%	2059
2023 Q1	–	Sell	-42	Closed	-$32K	–	2443
2022 Q4	$32K	Buy	+42	New	+$60.8K	﹤0.01%	2139

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

HIA

Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HRT Financial's ALZN Position: Q1 2024 in Review

HRT Financial sold out of Alzamend Neuro (ALZN) in Q1 2024, closing a stake of 187 shares — an estimated $15K sold.

HRT Financial first reported a position in ALZN in Q4 2022 and held it in 2 quarters. The position peaked at $32K in Q4 2022. 10 funds tracked by Wall St. Rank hold ALZN as of Q1 2024.

HRT Financial reported no remaining Alzamend Neuro position as of Q1 2024 after selling out during the quarter.
HRT Financial sold 187 Alzamend Neuro shares in Q1 2024, an estimated $15K.
HRT Financial first reported a position in Alzamend Neuro in Q4 2022 and held it in 2 quarters.
HRT Financial's Alzamend Neuro position peaked at $32K in Q4 2022.
10 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2024.

Based on HRT Financial's 13F filing for Q1 2024, filed 13 May 2024.